Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease

American Journal of the Medical Sciences

Volumn 342, Issue 5, 2011, Pages 383-387

  Maroni, Lorenzo ^a   Guasti, Luigina ^a   Castiglioni, Luana ^a   Marino, Franca ^a   Contini, Sara ^a   MacChi, Valentina ^a   De Leo, Alessandra ^a   Gaudio, Giovanni ^a   Tozzi, Matteo ^a   Grandi, Anna M ^a   Cosentino, Marco ^a   Venco, Achille ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Cardiovascular risk; Dyslipidemia; Liver enzymes; Nonalcoholic fatty liver disease; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GAMMA GLUTAMYLTRANSFERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG TARGETING; DYSLIPIDEMIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIPOPROTEIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80055036005     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318213e526     Document Type: Article

References (34)

1. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010;11:430-45.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346: 1221-31.
3. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001;50: 1844-50. (Pubitemid 33641605)
4. Liangpunsakul S, Chalasani N. Unexplained Elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the Third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005;329:111-6. (Pubitemid 40354750)
5. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45:1929-34.
6. Adiels M, Olofsson S, Taskinen, et al. Overproduction of very lowdensity lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-36.
7. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
8. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
9. Pasternak RC, Smith SC Jr, Noel Bairey-Merz C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-8. (Pubitemid 34925341)
10. Eidelman RS, Lamas GA, Hennekens CH. The new national cholesterol education program guidelines clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med 2002;162:2033-6. (Pubitemid 35168210)
11. Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 2004;109(suppl 1):III20-6.
12. Tessari P, Coracina A, Cosma A, et al. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009;19: 291-302.
13. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy a systematic overview of randomized clinical trials. Circulation 2006;114:2788-97. (Pubitemid 46018281)
14. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009;49:306-17.
15. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report national cholesterol education program. National Heart, Lung, and Blood Institute National Institutes of Health NIH Publication No. 02-5215, September 2002.
16. Grundy SM, Brewer HB Jr, Cleeman JI, et al. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-8. (Pubitemid 38133916)
17. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. J Am Med Assoc 2003;289:2560-72. (Pubitemid 37430158)
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(suppl 1):S55-60.
19. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73. (Pubitemid 46489550)
20. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischaemic heart disease. World J Gastroenterol 2005;11:4838-42.
21. Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease among type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006;23:403-9.
22. Fracanzani AF, Burdick L, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008;121:72-8.
23. Nichols GA, Ambegaonkar BM, Sazonov V, et al. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am J Cardiol 2009;104:1689-94.
24. Ioannou GN, Weiss NS, Boyko EJ, et al. Elevated serum alanine aminotrasferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145-51. (Pubitemid 43724639)
25. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007;27: 127-33. (Pubitemid 46360389)
26. Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28:2-12. (Pubitemid 351782816)
27. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008;57:1711-8.
28. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003;17:713-8. (Pubitemid 38072335)
29. Athyros VG, Dimitri P, Mikhailidis DP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873-83. (Pubitemid 43875555)
30. Chalasani N, Aljadey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92. (Pubitemid 38552793)
31. Vuppalanchi R, Evegenia T, Chalasani N. Patients with elevated baseline liver enzymes do not have major frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62-5. (Pubitemid 40250595)
32. Rallidis LS. Pravastatin in patients with non-alcoholic steathoheoatitis: results of a pilot study. Atherosclerosis 2004;174:193-6. (Pubitemid 38595458)
33. Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, et al. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-7. (Pubitemid 43727474)
34. Ekstedt M, Franzèn LE, Mathiesen UL, et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a hystopathological follow-up study. J Hepatol 2007;47: 135-41. (Pubitemid 46817693)